Benzo use linked to Alzheimer’s

The case-controlled study, described in a BMJ editorial as using “rigorous methods”, matched 1796 people aged over 66 with a diagnosis of Alzheimer’s with 7184 controls, using records from the administrative database of the Quebec public drug plan.

Benzodiazepine use for less than three months did not increase Alzheimer’s risk, but use for 3–6 months carried a 32% increase in risk, and use for over six months raised the risk by 84%, the authors wrote in the BMJ.

Further, the risk of Alzheimer’s was higher in patients taking long-acting benzodiazepines than